Transforming Our Discoveries into Therapeutics
 |
Aeolus Pharmaceuticals is developing AEOL 10150, a small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species. AEOL 10150 is currently undergoing human clinical evaluation in patients with ALS. James Crapo, MD, and Brian Day, PhD, of National Jewish Health are inventors on the intellectual property underlying this discovery. |
| |
|
 |
Juvaris BioTherapeutics was founded in 2003, based on the intellectual property developed at National Jewish Health by Steven Dow, DVM, PhD. Juvaris BioTherapeutics is developing therapeutic vaccines for cancer and infectious diseases using its novel technology platform of cationic lipids and non-coding DNA complexes. |
| |
|
|
|
OrPro Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company headquartered in San Diego, CA. The company's goal is to develop a breakthrough class of safe, well-tolerated and more effective inhaled non-systemic drugs based on the thioredoxin active site for the treatment of patients with cystic fibrosis (CF), COPD/emphysema, bronchiectasis, severe asthma, and other serious obstructive pulmonary diseases. OrPro's lead product, ORP-100, an aerosolized variant of recombinant human thioredoxin, will target abnormal viscosity due to excess protein gels in CF and has the potential for broader clinical efficacy than existing mucolytic approaches. OrPro is the exclusive licensee of intellectual property relating to the thioredoxin active site developed by pediatric pulmonologist Dr. Carl White, MD at National Jewish Health. |
| |
|
|
|
 |
Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Their three-pronged approach combines novel breakthroughs by Yosef Refaeli, PhD, John Cambier, PhD, and colleagues at National Jewish Health and University of Colorado Denver in cellular, biologic and small molecule approaches to treat and manage these diseases. |
| |
|
|
|
 |
Taligen Therapeutics, Inc., which was founded in March 2004 by Drs. Woody Emlen and V. Michael Holers, is working to develop and commercialize technologies created by scientists from National Jewish Health (Erwin Gelfand, MD) and the University of Colorado Denver. Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. The Company employs novel technologies designed to modulate and regulate activation of the complement system. |
| |
|
 |
VistaGen applies their innovative in vitro embryonic stem (ES) cell technologies to discover and develop new generation drugs and protein biologics, both internally and through strategic collaborations with the pharmaceutical and biotechnology industries. Vistagen's clinically predictive in vitro embryonic stem cell technologies are based on intellectual property developed at National Jewish Health by Gordon Keller, PhD. |
For more information, contact Emmanuel Hilaire at HilaireE@njhealth.org
